Heart Failure in Women

Current Heart Failure Reports

Volumn 12, Issue 2, 2015, Pages 187-195

  Taylor, Anne L ^a  

^a Department of Medicine   (United States)

^b Columbia University ^*  (United States)

Author keywords

Heart failure; Implantable defibrillator therapy; Peripartum cardiomyopathy; Resynchronization therapy; Ventricular remodeling; Women

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ISOSORBIDE DINITRATE;

CELL FUNCTION; CELL STRUCTURE; CLINICAL FEATURE; DEVICE THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; NONHUMAN; PREGNANCY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; PREGNANCY COMPLICATION;

FEMALE; HEART FAILURE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SEX FACTORS;

EID: 84925481966     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-015-0252-x     Document Type: Review

References (69)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399–410.
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344–50.50.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.
4. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med. 2009;169(7):708–15.
5. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–215.
6. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.
7. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.
8. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10(2):140–8.
9. Hsich EM, Piña IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54(6):491–8.
10. Chang P, Chia SY, Sim LL, Gao F, Lee FL, Chai P, et al. Impact of sex on clinical characteristics and in-hospital outcomes in a multi-ethnic Southeast Asian population of patients hospitalized for acute heart failure. ASEAN Heart J. 2014;22(1):42–7.
11. Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15(1):94–102. An analysis of survival and quality of life in a European cohort.
12. O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115(24):3111–20.
13. Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol. 2007;49(13):1450–8.
14. Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006;48(11):2263–7.
15. Galvao M, Kalman J, DeMarco T, Fonarow GC, Galvin C, Ghali JK, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail. 2006;12(2):100–7.
16. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52(5):347–56.
17. Diercks DB, Fonarow GC, Kirk JD, Emerman CL, Hollander JE, Weber JE, et al. Risk stratification in women enrolled in the Acute Decompensated Heart Failure National Registry Emergency Module (ADHERE-EM). Acad Emerg Med. 2008;15(2):151–8.
18. Chyu J, Fonarow GC, Tseng CH, Horwich TB. Four-variable risk model in men and women with heart failure. Circ Heart Fail. 2014;7(1):88–95.
19. Salton CJ, Chuang ML, O’Donnell CJ, Kupka MJ, Larson MG, Kissinger KV, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol. 2002;39(6):1055–60.
20. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol. 1995;26(4):1068–79.
21. Deschepper CF, Llamas B. Hypertensive cardiac remodeling in males and females: from the bench to the bedside. Hypertension. 2007;49(3):401–7.
22. Kanashiro-Takeuchi RM, Heidecker B, Lamirault G, Dharamsi JW, Hare JM. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. Clin Transl Sci. 2009;2(2):134–42.
23. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail. 2002;8(2):101–7.
24. Piro M, Della Bona R, Abbate A, Biasucci LM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol. 2010;55(11):1057–65.
25. Luchner A, Bröckel U, Muscholl M, Hense HW, Döring A, Riegger GA, et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res. 2002;53(3):720–7.
26. Montalvo C, Villar AV, Merino D, García R, Ares M, Llano M, et al. Androgens contribute to sex differences in myocardial remodeling under pressure overload by a mechanism involving TGF-β. PLoS One. 2012;7(4):e35635.
27. Rohde LE, Zhi G, Aranki SF, Beckel NE, Lee RT, Reimold SC. Gender-associated differences in left ventricular geometry in patients with aortic valve disease and effect of distinct overload subsets. Am J Cardiol. 1997;80(4):475–80. An excellent survey of inclusion of women in cardiovascular clinical trials.
28. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3(2):135–42.
29. Shekelle P, Rich M, Morton S, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol. 2003;41:1529–38.
30. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575–81.
31. Pfeffer MA, Swedberg K, Granger CG, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003;362:759–66.
32. Pitt B, Poole-Wilson PA, Segal R, On behalf of the ELITE II Investigators, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7.
33. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
34. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585–91.
35. Eichhorn E, Domanski M, Krause-Steinrauf H, For the Beta-Blocker Evaluation of Survival Trial Investigators, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–67.
36. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
37. Adams Jr KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497–504.
38. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–11.
39. Taylor A, Ziesche S, Yancy C, For the African-American Heart Failure Trial Investigators, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.
40. Chugh SS, Uy-Evanado A, Teodorescu C, Reinier K, Mariani R, Gunson K, et al. Women have a lower prevalence of structural heart disease as a precursor to sudden cardiac arrest: the Ore-SUDS (Oregon Sudden Unexpected Death Study). J Am Coll Cardiol. 2009;54(22):2006–11.
41. Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, et al. Prospective study of sudden cardiac death among women in the United States. Circulation. 2003;107(16):2096–101.
42. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA. 2007;298(13):1517–24.
43. Russo AM, Stamato NJ, Lehmann MH, Hafley GE, Lee KL, Pieper K, et al. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol. 2004;15(9):993–8.
44. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32.
45. Lampert R. Implantable cardioverter-defibrillator use and benefit in women. Cardiol Rev. 2007;15(6):298–303.
46. Russo AM, Poole JE, Mark DB, Anderson J, Hellkamp AS, Lee KL, et al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. J Cardiovasc Electrophysiol. 2008;19(7):720–4.
47. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7(7):876–82. An excellent analysis of outcomes of ICD use and outcomes by sex from a large database.
48. MacFadden DR, Crystal E, Krahn AD, Mangat I, Healey JS, Dorian P, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med. 2012;156(3):195–203.
49. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, et al. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation. 2012;125(9):1094–101. Excellent discussion of the outcomes by sex in the MADIT-CRT trial with discussion of other CRT trial data.
50. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011;57(7):813–20.
51. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.
52. Cheng A, Gold MR, Waggoner AD, Meyer TE, Seth M, Rapkin J, et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012;9(5):736–41.
53. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.
54. Verhaert D, Grimm RA, Puntawangkoon C, Wolski K, De S, Wilkoff BL, et al. Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol. 2010;55(17):1788–95. Outstanding meta-analysis of CRT use and outcomes in women.
55. Zusterzeel R, Selzman KA, Sanders WE, Caños DA, O’Callaghan KM, Carpenter JL, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med. 2014;174(8):1340–8.
56. Siu SC, Colman JM. Heart disease and pregnancy. Heart. 2001;85(6):710–15.
57. Siu SC, Colman JM, Sorensen S, Smallhorn JF, Farine D, Amankwah KS, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation. 2002;105(18):2179–84.
58. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104(5):51–521. Best recent review of HF in women with heart disease preexistent to pregnancy.
59. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Domènech MT, Grando-Ting J, Estensen M, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart. 2014;100(3):231–8.
60. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006;113(4):517–24.
61. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014;11(6):364–70+.
62. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J. 2011;87(1023):34–9.
63. Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy- a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol. 2008;199(4):e5–6. Excellent review of peripartum cardiomyopathy.
64. Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33–8.
65. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.
66. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005;73(2):123–30.
67. Go AS et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
68. Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010
69. NCHS data brief, no 108. Hyattsville, MD: National Center for Health Statistics. 2012